These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8549349)

  • 41. A pharmacokinetic study of E-4441, a new quinolone, in the rat, mouse and cynomolgus monkey.
    Martinez L; Basi N; Dordal A; Roser R; Sagarra R
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():352-6. PubMed ID: 1668199
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Experimental and clinical studies of temafloxacin in the field of obstetrics and gynecology].
    Matsuda S; Shimizu T; Cho N; Okada H
    Jpn J Antibiot; 1993 Jun; 46(6):492-504. PubMed ID: 8395608
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Premafloxacin: a projected veterinary use fluoro-quinolone with significant activity against multi-resistant gram-positive human pathogens.
    Zerva L; Marshall SA; Jones RN
    J Antimicrob Chemother; 1996 Oct; 38(4):742-4. PubMed ID: 8937972
    [No Abstract]   [Full Text] [Related]  

  • 44. Pharmacokinetics of prulifloxacin. 2nd communication: pharmacokinetics and effect on hepatic drug-metabolizing enzyme activities after repeated administration and transfer into fetus and milk after a single administration in rats.
    Okuyama Y; Momota K; Morino A
    Arzneimittelforschung; 1997 Mar; 47(3):285-92. PubMed ID: 9105547
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Clinical and bacteriological study of sparfloxacin on bacterial prostatitis].
    Suzuki K; Horiba M; Naide Y; Shinoda M; Hibi H
    Hinyokika Kiyo; 1992 Jan; 38(1):121-8. PubMed ID: 1312292
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetic study of danofloxacin in cattle and swine.
    Mann DD; Frame GM
    Am J Vet Res; 1992 Jun; 53(6):1022-6. PubMed ID: 1320812
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Pharmacodynamic and pharmacokinetic approaches to optimization of lomefloxacin].
    Iakovlev SV
    Antibiot Khimioter; 1998; 43(10):42-5. PubMed ID: 9825110
    [No Abstract]   [Full Text] [Related]  

  • 48. [How are quinolones used in clinical practice? Gyrase antagonists from the viewpoint of the hospital pharmacist].
    Schurz JK
    Pharm Unserer Zeit; 2001; 30(5):400-5. PubMed ID: 11575176
    [No Abstract]   [Full Text] [Related]  

  • 49. The measurement of a new antimicrobial quinolone in hair as an index of drug exposure.
    Uematsu T; Nakano M; Akiyama H; Nakashima M
    Br J Clin Pharmacol; 1993 Feb; 35(2):199-203. PubMed ID: 8382934
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin.
    Child J; Andrews JM; Wise R
    Antimicrob Agents Chemother; 1995 Feb; 39(2):513-5. PubMed ID: 7726523
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Review [new antimicrobial agent series XLI]: lomefloxacin].
    Soejima R; Matsumoto F
    Jpn J Antibiot; 1991 Oct; 44(10):1045-60. PubMed ID: 1662290
    [No Abstract]   [Full Text] [Related]  

  • 52. Quinolones in perspective.
    Neu HC
    J Antimicrob Chemother; 1990 Oct; 26 Suppl B():1-6. PubMed ID: 2258336
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone.
    Park HS; Kim HJ; Seol MJ; Choi DR; Choi EC; Kwak JH
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2261-4. PubMed ID: 16723601
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The importance of fluoroquinolones in treating pneumonia in the elderly].
    Belousov IuB; Efremenkova OV; Sokolov AV; Tishenkova IF
    Antibiot Khimioter; 1999; 44(12):23-6. PubMed ID: 10687030
    [No Abstract]   [Full Text] [Related]  

  • 55. Effect of age and gender on the pharmacokinetics of grepafloxacin.
    Efthymiopoulos C; Bramer SL; Maroli A
    Clin Pharmacokinet; 1997; 33 Suppl 1():9-17. PubMed ID: 9433651
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Grepafloxacin--focus on respiratory infections.
    Geddes AM
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():1-4. PubMed ID: 9484866
    [No Abstract]   [Full Text] [Related]  

  • 57. Laboratory and clinical study of balofloxacin (Q-35), a new fluoroquinolone, in urinary tract infection.
    Suzuki K; Horiba M; Ishikawa K; Katoh S; Naide Y; Yanaoka M; Andoh S
    Drugs; 1995; 49 Suppl 2():376-8. PubMed ID: 8549367
    [No Abstract]   [Full Text] [Related]  

  • 58. Drug not considered a first-line agent.
    Lexchin J
    Can Fam Physician; 1998 Nov; 44():2376. PubMed ID: 9839049
    [No Abstract]   [Full Text] [Related]  

  • 59. Accumulation of a newly developed fluoroquinolone, OPC-17116, by human polymorphonuclear leukocytes.
    Taira K; Koga H; Kohno S
    Antimicrob Agents Chemother; 1993 Sep; 37(9):1877-81. PubMed ID: 8239600
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Physiologically-based pharmacokinetic analysis of grepafloxacin.
    Nakajima Y; Hattori K; Shinsei M; Matsunaga N; Iizasa H; Sasabe H; Akiyama H; Miyanmoto G; Nakashima E
    Biol Pharm Bull; 2000 Sep; 23(9):1077-83. PubMed ID: 10993208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.